|Mr. Eutillio Buccilli CPA||Chief Exec. Officer & Exec. Director||438.88k||N/A||64|
|Mr. Kevin Fischer CPA, AGIA, ACIS, B.Com.||CFO & Company Sec.||146.77k||N/A||N/A|
|Dr. Richard Allman Ph.D.||Scientific Director||N/A||N/A||57|
|Ms. Diana Newport||Quality and Bus. Operations Director||114.29k||N/A||60|
|Mr. Chris Saunders MBA, B.S.||VP of Sales & Marketing - Phenogen Sciences Inc||233.67k||N/A||N/A|
Genetic Technologies Limited operates as a molecular diagnostics company that offers predictive testing and assessment tools to help physicians in managing womens health. The companys lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. Genetic Technologies Limited markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons primarily in Australia and the United States. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.
Genetic Technologies Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.